OncotargetJrnl Profile Banner
Oncotarget Journal Profile
Oncotarget Journal

@OncotargetJrnl

Followers
81
Following
2K
Media
1
Statuses
477

For the latest news and updates from Oncotarget, please follow us @Oncotarget.

Orchard Park, NY
Joined December 2019
Don't wanna be here? Send us removal request.
@Oncotarget
Oncotarget
9 days
🔆 #PaperSpotlight: "Anti-DNA virus agent cidofovir - loaded green synthesized cerium oxide nanoparticles (Nanoceria): Nucleic acids (DNA and RNA) binding affinity and cytotoxicity effects" #PressRelease ⬇️ https://t.co/1JYuCwKqYA #cancer #oncology #research #press #publishing
Tweet card summary image
oncotarget.com
“This environmentally friendly technique represents a novel approach to nanoparticle fabrication, emphasizing sustainability in nanotechnology.”
0
1
0
@Oncotarget
Oncotarget
1 month
🔆 #PaperSpotlight: "Widespread folate receptor expression in pediatric and adolescent solid tumors - opportunity for intraoperative visualization with the novel fluorescent agent pafolacianine" #PressRelease ⬇️ https://t.co/XE9p8dpkO0 #cancer #research #oncology #pafolacianine
Tweet card summary image
oncotarget.com
“​​This pre-clinical study demonstrates a broad potential application for pafolacianine in pediatric solid tumor resection.”
0
1
0
@Oncotarget
Oncotarget
1 month
📈 #TrendingWithImpact: "ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and..." #PressRelease ⬇️ https://t.co/hkO8AA9pfw #research
Tweet card summary image
oncotarget.com
“ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.”
0
1
0
@Oncotarget
Oncotarget
2 months
📈 #TrendingWithImpact: "Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma" #PressRelease ⬇️ https://t.co/6a02Dwzeah #cancer #ovariancancer #oa
Tweet card summary image
oncotarget.com
“These results highlight potential mechanisms by which loss of p53 function contributes to an immunosuppressive microenvironment in HGSC, and provide insight into the role of ovarian and peritoneal...
0
1
0
@Oncotarget
Oncotarget
3 months
📈 #TrendingWithImpact: This #research paper was #published in Volume 16, titled "The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo." #PressRelease ⬇️ https://t.co/zU3M6PVOuR #cancer #oncology #tumors #oa #publishing #press
oncotarget.com
“We determined in GI tumor cells that regorafenib interacted with aramchol to promote tumor cell killing.”
0
1
0
@Oncotarget
Oncotarget
3 months
🔆 #PaperSpotlight: "Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay" #PressRelease ⬇️ https://t.co/Ez32CMHnTe #research #precisiononcology #press #oa
Tweet card summary image
oncotarget.com
“Accordingly, MI Cancer Seek represents a safe and effective comprehensive molecular test option supporting biomarker-directed care for oncology patients.”
1
1
0
@Oncotarget
Oncotarget
3 months
📈 #TrendingWithImpact: "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion." #PressRelease ⬇️ https://t.co/aRZf3d9TUZ #cancer #breastcancer #press #research
Tweet card summary image
oncotarget.com
“The ability of PCAIs to mitigate various cancer hallmarks in the various cancer cell lines has been well established.”
0
1
0
@Oncotarget
Oncotarget
3 months
🔆 #PaperSpotlight: Thi #researchpaper was recently #published in Volume 16: "Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer." #PressRelease ⬇️ https://t.co/gwGVULDI0n #cancer #prostatecancer #research #oa
0
1
0
@Oncotarget
Oncotarget
4 months
🔆 #PaperSpotlight: "Extracorporeal blood filtration leading to tumor growth arrest and reduced analgesic requirements in Stage IV poorly differentiated pancreatic adenocarcinoma: A case report." #PressRelease ⬇️ https://t.co/aQK2FMU0RX #cancer #pancreaticcancer #oa #press
Tweet card summary image
oncotarget.com
“Therapeutic modalities that explore CTC removal via blood filtration may potentially have promising clinical benefits.”
0
1
0
@Oncotarget
Oncotarget
4 months
📈 #TrendingWithImpact: This #research paper was #published in Volume 16, entitled "A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment." #PressRelease ⬇️ https://t.co/4sv5rDHbww #cancer #press
Tweet card summary image
oncotarget.com
“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME.”
0
1
0